Want to stay smart? Sign up for a FREE 7-day trial today!
Spoon Feed —
In patients with CKD and gout, acute flares should avoid NSAIDs and consider either dose-adjusted colchicine, oral steroids, or intra-articular steroids; for urate lowering, start low and go slow with allopurinol.
Source
Gout Management in Patients With CKD. Am J Kidney Dis. 2025 Jul 1:S0272-6386(25)00924-2. doi: 10.1053/j.ajkd.2025.04.020. Epub ahead of print. PMID: 40609855
Spoon Feed —
When starting a patient with gout on urate-lowering therapy, preferentially choose colchicine over NSAIDs for gout flare prophylaxis, since NSAIDs are associated with increased cardiovascular risk.
Source
Comparative Cardiovascular Safety of NSAID versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients with Gout: Target Trial Emulations. Arthritis Rheumatol. 2025 May 26. doi: 10.1002/art.43259. Epub ahead of print. PMID: 40415645
Spoon Feed —
In a randomized, single-blinded, multicenter Chinese study, physical therapy was superior to glucocorticoid injections over one year for subjective knee pain and function.
Source
Physical therapy vs. glucocorticoid injection in patients with meniscal tears and knee osteoarthritis: a multi-center, randomized, controlled trial. BMC Med. 2025 May 9;23(1):277. doi: 10.1186/s12916-025-04113-y. PMID: 40346599
Spoon Feed —
In this retrospective multi-center study, a machine learning model trained to predict Kawasaki Disease performed with over 89% accuracy.
Source
External Validation of a Machine Learning Model to Diagnose Kawasaki Disease. J Pediatr. 2025 Mar 21;282:114543. doi: 10.1016/j.jpeds.2025.114543. Epub ahead of print. PMID: 40122277
Spoon Feed —
Upadacitinib 15 mg plus a 26-week steroid taper induced higher rates of sustained remission in giant-cell arteritis (GCA) than placebo plus a 52-week steroid taper.
Source
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025 Apr 2. doi: 10.1056/NEJMoa2413449. Epub ahead of print. PMID: 40174237
Spoon Feed —
In patients with thrombotic antiphospholipid syndrome (APS), warfarin is generally superior to direct oral anticoagulant (DOAC) therapy for secondary thrombosis prevention.
Source
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12. PMID: 30002145
Spoon Feed —
The addition of obinutuzumab as an adjunct to standard treatment for lupus nephritis resulted in significantly more complete renal recovery but higher risk of infection.
Source
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2410965. Epub ahead of print. PMID: 39927615
Spoon Feed —
In hereditary angioedema, gene therapy to downregulate kallikrein is being studied. Phase 2 trials show safety and promising efficacy.
Source
CRISPR-Based Therapy for Hereditary Angioedema. N Engl J Med. 2025 Jan 30;392(5):458-467. doi: 10.1056/NEJMoa2405734. Epub 2024 Oct 24. PMID: 39445704
Spoon Feed —
Over 90% of patients with MIS-C have a full recovery by 6 months after hospital discharge, including normalization of cardiovascular complications.
Source
Six-Month Outcomes in the Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children Study. JAMA Pediatr. 2025 Mar 1;179(3):293-301. doi: 10.1001/jamapediatrics.2024.5466. PMID: 39804656
Spoon Feed —
Dazukibart is a neutralizing monoclonal antibody against interferon-β (IFNβ) which shows effectiveness and safety for patients with moderate-to-severe, treatment-refractory cutaneous dermatomyositis.
Source
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025 Jan 11;405(10473):137-146. doi: 10.1016/S0140-6736(24)02071-3. PMID: 39798982